DexCom, Inc. $DXCM Shares Sold by Alamar Capital Management LLC

Alamar Capital Management LLC lessened its position in DexCom, Inc. (NASDAQ:DXCM) by 53.3% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 15,335 shares of the medical device company’s stock after selling 17,533 shares during the quarter. Alamar Capital Management LLC’s holdings in DexCom were worth $1,032,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Andra AP fonden acquired a new position in DexCom in the 2nd quarter valued at $26,000. Twin Peaks Wealth Advisors LLC purchased a new position in DexCom in the 2nd quarter valued at $26,000. SJS Investment Consulting Inc. boosted its stake in DexCom by 4,800.0% during the 3rd quarter. SJS Investment Consulting Inc. now owns 392 shares of the medical device company’s stock worth $26,000 after purchasing an additional 384 shares during the last quarter. Financial Consulate Inc. acquired a new stake in DexCom during the 3rd quarter worth $29,000. Finally, Migdal Insurance & Financial Holdings Ltd. purchased a new stake in shares of DexCom during the second quarter worth $45,000. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

DexCom Stock Down 3.7%

Shares of DXCM opened at $68.10 on Monday. DexCom, Inc. has a 52-week low of $54.11 and a 52-week high of $89.98. The company has a quick ratio of 1.59, a current ratio of 1.88 and a debt-to-equity ratio of 0.45. The stock has a fifty day simple moving average of $70.69 and a two-hundred day simple moving average of $68.75. The company has a market capitalization of $26.21 billion, a PE ratio of 32.43, a price-to-earnings-growth ratio of 1.32 and a beta of 1.48.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, February 12th. The medical device company reported $0.68 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.03. DexCom had a net margin of 17.94% and a return on equity of 32.12%. The firm had revenue of $1.26 billion for the quarter, compared to analysts’ expectations of $1.25 billion. During the same quarter in the previous year, the company posted $0.45 EPS. The company’s revenue was up 13.1% compared to the same quarter last year. As a group, equities analysts forecast that DexCom, Inc. will post 2.03 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have recently commented on DXCM. BTIG Research reiterated a “buy” rating and issued a $85.00 target price on shares of DexCom in a research report on Wednesday, February 25th. Wells Fargo & Company lowered their price target on shares of DexCom from $93.00 to $85.00 and set an “overweight” rating on the stock in a research report on Friday, February 13th. Piper Sandler reaffirmed an “overweight” rating on shares of DexCom in a research note on Thursday, February 5th. Leerink Partners reiterated an “outperform” rating and issued a $92.00 price objective on shares of DexCom in a report on Tuesday, December 16th. Finally, Truist Financial reissued a “buy” rating and issued a $80.00 target price (down from $82.00) on shares of DexCom in a research note on Tuesday, February 17th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, DexCom has an average rating of “Moderate Buy” and an average price target of $85.18.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.